MMC Comparisons.

<p>MMC Comparisons.</p

Gating strategy for activation panel (upper) and memory panel (lower).

<p>The sequential gating to CD3+ T cells is the same for both panels as shown in the upper row for each panel. Gating on CD4+ and CD8+ T cells is shown in the lower left graph in each panel. Markers of interest for each panel for CD4+ and CD8+ T cells are shown in the remaining plots.</p

Selected PBMC data for CD4+, CD8+, CD4+CCR5+, CD8+CCR5+, CD4+CD38+DR+, and CD8+CD38DR+ T cells (boxplots showing the median, quartiles, and range for each cell population).

<p>Selected PBMC data for CD4+, CD8+, CD4+CCR5+, CD8+CCR5+, CD4+CD38+DR+, and CD8+CD38DR+ T cells (boxplots showing the median, quartiles, and range for each cell population).</p

PBMC Comparisons.

<p>PBMC Comparisons.</p

qPBMC Comparisons.

<p>qPBMC Comparisons.</p

Selected MMC data for: CD4+, CD8+, CD4+CCR5+, CD8+CCR5+, CD4+CD38+DR+, and CD8+CD38DR+ T cells (boxplots showing the median, quartiles, and range for each cell population).

<p>Selected MMC data for: CD4+, CD8+, CD4+CCR5+, CD8+CCR5+, CD4+CD38+DR+, and CD8+CD38DR+ T cells (boxplots showing the median, quartiles, and range for each cell population).</p

Monoclonal antibody reagents used in the study.

<p>Monoclonal antibody reagents used in the study.</p

Study Populations.

<p>Study Populations.</p

Fluorescence-minus-one (FMO) controls for the activation panel.

<p>Shown is an example from one experiment at one site. The upper graphs show the FMO for APC CD69, the middle for PE CD38, and the lower for FITC HLA-DR. The three specimen types are shown with MMC on the left, PBMC in the middle and qPBMC on the right. For each, graphs are paired with the full stain on the left and the FMO on the right. Note that the FMO defines the lower limit of the gate; often the gate is placed higher.</p

Study flow diagram.

<p>Paired measures from compartment concentrations (CC) and both CC and biopsy samples (*) taken at the bolded visits: V3 (Visit 3: ∼30 mins post single oral dose), V5 (1–6 days post V3 dose), V6 (7–9 days post V3 dose), V7 (∼30 mins post single topical dose), V9 (1–3 days post V7 dose), V10 (7–12 days post V7 does) and V12 (∼30 mins post 7^th daily dose) used in the dose-response analysis.</p